Cargando…

Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study

Elagolix sodium salt is the first marketed orally active non-peptide gonadotropin-releasing hormone receptor antagonist (GnRHR-ant) for the management of hormone dependent diseases, such as endometriosis and uterine fibroids. Despite its presence on the market since 2018, a thorough NMR analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciceri, Samuele, Colombo, Diego, Fassi, Enrico M. A., Ferraboschi, Patrizia, Grazioso, Giovanni, Grisenti, Paride, Iannone, Marco, Castellano, Carlo, Meneghetti, Fiorella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180344/ https://www.ncbi.nlm.nih.gov/pubmed/37175271 http://dx.doi.org/10.3390/molecules28093861

Ejemplares similares

Crystallographic and NMR Investigation of Ergometrine and Methylergometrine, Two Alkaloids from Claviceps Purpurea
por: Meneghetti, Fiorella, et al.
Publicado: (2020)

A New Chemoenzymatic Synthesis of the Chiral Key Intermediate of the Antiepileptic Brivaracetam
por: Ciceri, Samuele, et al.
Publicado: (2018)

Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic
por: Ferraboschi, Patrizia, et al.
Publicado: (2021)

An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis
por: Mori, Matteo, et al.
Publicado: (2021)

Heat-Treated Lysozyme Hydrochloride: A Study on Its Structural Modifications and Anti-SARS-CoV-2 Activity
por: Delbue, Serena, et al.
Publicado: (2023)

Ovotransferrin Supplementation Improves the Iron Absorption: An In Vitro Gastro-Intestinal Model
por: Galla, Rebecca, et al.
Publicado: (2021)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Crystallographic and spectroscopic characterization of racemic Mosher’s Acid
por: Savich, Carolyn Z., et al.
Publicado: (2020)

Crystallographic and spectroscopic snapshots reveal a dehydrogenase in action
por: Huo, Lu, et al.
Publicado: (2015)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Crystallographic and spectroscopic characterization of (R)-O-acetylmandelic acid
por: Cirbes, Cady, et al.
Publicado: (2016)

Thermal, Spectroscopic, and Crystallographic Analysis of Mannose-Derived Linear Polyols
por: Mattsson, Ida, et al.
Publicado: (2018)

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
por: Archer, David F., et al.
Publicado: (2020)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Crystallographic Study of the LUMI Intermediate of Squid Rhodopsin
por: Murakami, Midori, et al.
Publicado: (2015)

Crystallographic and Spectroscopic Insights into Heme Degradation by Mycobacterium tuberculosis MhuD
por: Graves, Amanda B., et al.
Publicado: (2014)

Crystallographic and spectroscopic assignment of the proton transfer pathway in [FeFe]-hydrogenases
por: Duan, Jifu, et al.
Publicado: (2018)

Crystallographic and spectroscopic characterization of 3-chloro-5-fluorosalicylaldehyde
por: Triggs, Christopher T., et al.
Publicado: (2020)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Crystal Forms of the Antihypertensive Drug Irbesartan: A Crystallographic, Spectroscopic, and Hirshfeld Surface Analysis Investigation
por: Araya-Sibaja, Andrea Mariela, et al.
Publicado: (2022)

Crystallographic and spectroscopic characterization of 5-chloropyridine-2,3-diamine
por: Sulovari, Aron, et al.
Publicado: (2017)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Synthesis and Conformational Analysis of Hydantoin-Based Universal Peptidomimetics
por: Caramiello, Alessio M., et al.
Publicado: (2022)

Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition
por: Capelli, Davide, et al.
Publicado: (2023)

Thiabendazole and Thiabendazole-Formic Acid Solvate: A Computational, Crystallographic, Spectroscopic and Thermal Study
por: Tabanez, Andreia M., et al.
Publicado: (2020)

Crystallographic and Spectroscopic Investigations on Oxidative Coordination in the Heteroleptic Mononuclear Complex of Cerium and Benzoxazine Dimer
por: Wattanathana, Worawat, et al.
Publicado: (2021)

The Close Interaction of a C−F Bond with an Amide Carbonyl: Crystallographic and Spectroscopic Characterization
por: Harry, Stefan Andrew, et al.
Publicado: (2022)

Spectroscopic, Crystallographic, and Electrochemical Study of Different Manganese(II)‐Substituted Keggin‐Type Phosphomolybdates
por: Raabe, Jan‐Christian, et al.
Publicado: (2022)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Synthesis and Characterization of New Triazole-Bispidinone Scaffolds and Their Metal Complexes for Catalytic Applications
por: Rossetti, Arianna, et al.
Publicado: (2023)

Design of efficient artificial enzymes using crystallographically-enhanced conformational sampling
por: Rakotoharisoa, Rojo V., et al.
Publicado: (2023)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqhpcoo3dmcfabbk1lld8cp7ud